论文部分内容阅读
目的:对PreS1抗原定量在恩替卡韦抗乙肝病毒治疗中的临床应用情况予以探究并分析。方法:随机选取我院自2013年10月2014年10月期间收治的乙肝病毒患者共100例作为本次研究对象,观察所有被研究对象采用PreS1抗原定量判断实施恩替卡韦治疗前后的应用效果。结果:对比分析乙肝病毒患者实施恩替卡韦治疗前后的具体情况,经PreS1抗原定量指标分析后,表明多次动态观察其检测结果对比差异具有统计学意义,P<0.05。结论:将PreS1抗原定量应用于乙肝病毒患者的诊断及疗效观察中,根据检测结果为患者后期治疗和干预提供了较高的医学指导和参考。
OBJECTIVE: To investigate the clinical application of PreS1 antigen quantitation in the treatment of hepatitis B virus (HBV) with entecavir. Methods: A total of 100 hepatitis B patients admitted to our hospital from October 2013 to October 2014 were randomly selected for this study. All the subjects were observed using PreS1 antigen to quantitatively evaluate the effect of entecavir treatment before and after treatment. Results: Comparing the specific situation before and after entecavir treatment in patients with hepatitis B virus, the quantitative analysis of PreS1 antigen showed that there were significant differences in the results of multiple dynamic observation (P <0.05). Conclusion: The quantitative determination of PreS1 antigen in patients with hepatitis B virus diagnosis and efficacy of observation, based on the results of the test for patients with post-treatment and intervention provides a high medical guidance and reference.